Lilly paid $140m up front for an option to acquire Radionetics for $1bn within an undisclosed timeframe. The private firm is developing small molecule GPCR-targeted radiopharmaceuticals.

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds. 

Teva continues to find comfort with an ally on biosimilar development, striking a deal with the Fresenius-Kabi-backed mAbxience for an undisclosed oncology biosimilar.

The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.